In vitro translational activity of messenger RNA following treatment of human colon carcinoma cells with sangivamycin.
Total mRNA from human colon carcinoma cell line HT-29 treated with the pyrrolopyrimidine antibiotic, sangivamycin(7-deaza-7-carboxamidoadenosine), was assessed in vitro using a reticulocyte lysate translation system. Under conditions of known drug-induced cell lethality, sangivamycin-modified mRNA showed a diminished translational capacity. The decreased activity of drug-modified mRNA increased in proportion to the time-dependent cytocidal effects of sangivamycin in this cell line. These data suggest that the lethal effects of this drug may be associated, in part, with a reduced ability of drug-modified mRNA to sustain translation in situ.
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002474:Cell-Free System; D002478:Cells, Cultured; D003110:Colonic Neoplasms; D006801:Humans; D014176:Protein Biosynthesis / Q000187:drug effects*; D011741:Pyrimidine Nucleosides / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000378:metabolism*; D012156:Reticulocytes
D000903:Antibiotics, Antineoplastic; D011741:Pyrimidine Nucleosides; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C005699:sangivamycin